Shares of Humana Inc. (NYSE: HUM) advanced 2.6% to $382.52 in Wednesday morning trading, as investors focused on a favorable preliminary estimate for the 2027 Social Security cost-of-living adjustment (COLA). The latest CPI-W data for July suggests a COLA of approximately 3.1%, but a closer look reveals that medical inflation remains a persistent challenge for the Medicare Advantage insurer.
The COLA estimate is based on the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W), which showed no change in July on an unadjusted basis. However, medical-care services rose 0.6% during the month, and overall medical care increased 0.4% on a seasonally adjusted basis. Prescription drug prices declined 0.8%, offering some offset but not enough to ease concerns about healthcare cost trends.
Social Security calculates the annual COLA by comparing the average CPI-W from July through September of the current year with the same period in the prior year. The July 2026 index level of 327.104 is 3.1% above the third-quarter 2025 average of 317.265, but the final figure will depend on August and September data. If the 3.1% increase holds, the average retired-worker benefit would rise by roughly $64 per month, based on the projected 2026 average benefit of $2,071.
For Humana, the COLA is not a direct driver of its Medicare Advantage premiums. Those rates are determined by federal payments, member risk profiles, and medical utilization. The company's second-quarter results highlighted the pressure: the insurance benefit ratio reached 91.2%, up from 89.9% a year earlier, leaving just 8.8 cents of each premium dollar before operating expenses. The full-year midpoint of 92.75% leaves even less room.
Revenue for the second quarter jumped 26.2% to $40.87 billion, and adjusted EPS rose 21.4% to $7.61. However, adjusted insurance operating income grew only 7.0% to $824 million, a slower pace than revenue, reflecting the higher benefit ratio. CEO Jim Rechtin said first-half results were "right where we said we'd be," citing improved clinical care and efficiency, and the company maintained its full-year adjusted EPS guidance of at least $9.00.
Humana expects individual Medicare Advantage membership to expand by about 25% this year, which increases scale but also amplifies the financial impact of any pricing or utilization missteps. Analysts remain cautiously optimistic, with a consensus Moderate Buy rating and an average price target of $395.22, just 3.3% above Wednesday's price. Recent price target hikes from JPMorgan, Morgan Stanley, Barclays, Piper Sandler, and Guggenheim reflect growing confidence, but the stock's upside appears limited.
Key risks include higher-than-expected medical utilization, reduced Medicare Star Ratings impacting 2026 earnings, and the possibility that the final COLA deviates from the preliminary estimate. While the COLA provides helpful context for household finances, Humana's earnings are more directly tied to benefit costs, federal payment rates, and its ability to manage the planned membership surge.
Investors should watch upcoming CPI-W releases for August and September, as well as Humana's third-quarter earnings, for signs of whether medical cost trends are stabilizing. The company's narrow margin leaves little room for error, and any acceleration in healthcare inflation could weigh on the stock despite the positive COLA headline.
